WallStreetZenWallStreetZen

NASDAQ: ALGS
Aligos Therapeutics Inc Earnings & Revenue

OverviewForecastEarnings
DividendOwnership

ALGS past revenue growth

How has ALGS's revenue growth performed historically?
Company
11.66%
Industry
148.64%
Market
17.33%
ALGS's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
ALGS's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Market Performance
ALGS's revenue growth is accelerating... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

ALGS earnings and revenue history

Current Revenue
$15.5M
Current Earnings
-$87.7M
Current Profit Margin
-564.6%

ALGS Return on Equity

Current Company
-116.4%
Current Industry
-63.5%
Current Market
188%
ALGS's Return on Equity (-116.4%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when ALGS announces earnings.

ALGS Return on Assets

Current Company
-75.4%
Current Industry
2.9%
ALGS is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

ALGS Return on Capital Employed

Current Company
-69.05%
Current Industry
19.5%
ALGS's ability to generate Return... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

ALGS vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
ALGS$15.53M-$85.06M-$87.68M+88.75%N/A
CELU$14.79M-$169.66M-$181.41M-81.46%N/A
LTRN$0.00-$15.79M-$15.96MN/AN/A
MURA$0.00-$192.72M-$207.45MN/AN/A
CLGN$10.96M-$6.41M-$7.02M+16.93%N/A
View Top Biotech Stocks

ALGS earnings dates

Next earnings date
May 2, 2024

Aligos Therapeutics Earnings & Revenue FAQ

What were ALGS's earnings last quarter?

On Invalid Date, Aligos Therapeutics (NASDAQ: ALGS) reported Q4 2023 earnings per share (EPS) of $0.02, up 103.92% year over year. Total Aligos Therapeutics earnings for the quarter were -$27.89 million. In the same quarter last year, Aligos Therapeutics's earnings per share (EPS) was -$0.51.

If you're new to stock investing, here's how to buy Aligos Therapeutics stock.

What was ALGS's earnings growth in the past year?

As of Q2 2024, Aligos Therapeutics's earnings has grown year over year. Aligos Therapeutics's earnings in the past year totalled -$87.68 million.

What is ALGS's earnings date?

Aligos Therapeutics's earnings date is Invalid Date. Add ALGS to your watchlist to be reminded of ALGS's next earnings announcement.

What was ALGS's revenue last quarter?

On Invalid Date, Aligos Therapeutics (NASDAQ: ALGS) reported Q4 2023 revenue of $2.68 million up 24.2% year over year. In the same quarter last year, Aligos Therapeutics's revenue was $3.54 million.

What was ALGS's revenue growth in the past year?

As of Q2 2024, Aligos Therapeutics's revenue has grown 11.66% year over year. This is 136.97 percentage points lower than the US Biotechnology industry revenue growth rate of 148.64%. Aligos Therapeutics's revenue in the past year totalled $15.53 million.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.